GLP-1 Drugs Do Not Change Injection Needs for Diabetic Macular Edema, Study Finds

GLP-1 receptor agonists did not significantly change how often patients with diabetic macular edema needed anti-VEGF injections, according to a large retrospective cohort study presented at the American Academy of Ophthalmology meeting in New Orleans. Over 24 months of follow-up, treatment frequency showed no sustained or progressive change after patients started a GLP-1 drug, compared with matched patients who did not. Visual acuity and retinal thickness also held steady. Researchers said the results are reassuring amid ongoing uncertainty about the drugs' eye safety, though they cautioned that more research is needed.

Patients with diabetic macular edema (DME) who started GLP-1 receptor agonists did not need more or fewer anti-VEGF injections, a large retrospective study found. The research was presented at the American Academy of Ophthalmology (AAO) meeting.

Over 24 months of follow-up, there was \

Read next

GLP-1 Medications Show Promise in Treating Obesity and Improving Fertility

GLP-1 Medications Show Promise in Treating Obesity and Improving Fertility

Research on GLP-1 medications has yielded promising results in treating obesity and improving fertility in men with low testosterone. A study found that GLP-1s may improve testosterone levels and sperm quality, while another study showed a 310-fold increase in GLP-1 prescriptions for children with obesity.

Medicare to Offer Cheaper GLP-1 Weight Loss Medications to Seniors

Medicare to Offer Cheaper GLP-1 Weight Loss Medications to Seniors

A new pilot program will allow some Medicare recipients to access GLP-1 weight loss medications for $50 a month, potentially helping millions of older adults who struggle with obesity. The program, set to launch on July 1, will cover three drugs and be available to those with Medicare Part D who meet certain conditions.